Add like
Add dislike
Add to saved papers

Toll Like Receptor-7 and -9 agonists improve Hepatitis C Virus replication and infectivity inhibition by plasmacytoid dendritic cells.

Journal of Virology 2018 September 20
Plasmacytoid dendritic cells (pDCs) are innate immune cells with high antiviral activity triggered by Toll like receptor (TLR)-7 and -9 stimulation. Moreover, they are important mediators between innate and adaptive immunity. Although nowadays there is available an effective therapeutic arsenal against hepatitis C virus (HCV), a protective vaccine is not available. We have analyzed the pDCs response to HCV infection in a HCV-Huh7.5 virus-cell system, which allows completing the virus infectious cycle. pDCs were cocultured following human immunodeficiency virus (HIV) aldrithiol-2 inactivated (AT-2) (TLR-7 agonist) and CpG (TLR-9 agonist) stimulation. We employed three virus derivatives, a wild type Jc1, an interferon-resistant virus IR, and a high replicative fitness virus P100, in order to explore additional IFN-α-related virus inhibition mechanisms. pDCs inhibited HCV infectivity and replication, and produced IFN-α. After TLR-7 and TLR-9 stimulation, inhibition of infectivity and IFN-α production by pDCs were enhanced. TLR-7 stimulation drove a higher TNF-related apoptosis-inducing ligand (TRAIL) expression in pDCs. Additionally, TLR-7 and TLR-9 stimulated pDCs exhibited a mature phenotype, improving the antigen presentation and lymph node homing related markers. In conclusion, pDCs could serve as a drug target against HCV in order to improve antiviral activity and as an enhancer of viral immunization. IMPORTANCE We implemented a coculture system of pDCs with HCV-infected hepatoma cell line, Huh7.5. We used three HCV derivatives in order to gain insight into pDCs behavior against HCV and associated antiviral mechanisms. The results with this cell coculture system support the capacity of pDCs to inhibit HCV replication and infectivity mainly via IFN-α, but also through additional mechanisms associated with pDC maturation. We provided evidence that TLR agonists can enhance antiviral pDCs function and can induce phenotypic changes that may facilitate the interplay with other immune cells. These findings suggest the possibility of including TLR agonists in the strategies of HCV vaccine development.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app